(Q36739226)

16 August 2017

1 reference

title

Prevention and management of ovarian hyperstimulation syndrome (English)

1 reference

16 August 2017

Nikos F Vlahos

1

1 reference

16 August 2017

Odysseas Gregoriou

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

Annals of the New York Academy of Sciences

16 August 2017

published in

1 reference

16 August 2017

volume

1092

1 reference

16 August 2017

page(s)

247-264

1 reference

The ovarian hyperstimulation syndrome

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Ovarian hyperstimulation syndrome complicating a spontaneous singleton pregnancy: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

The role of enalapril in the prevention of ovarian hyperstimulation syndrome: a rabbit model

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Thromboembolic complications associated with reproductive endocrinologic procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Angiogenesis-like activity of endothelial cells co-cultured with VEGF-producing smooth muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Angiogenic activity of swine granulosa cells: effects of hypoxia and the role of VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Presence and absence of follicle-stimulating hormone receptor mutations provide some insights into spontaneous ovarian hyperstimulation syndrome physiopathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680Asn polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Modulation of ligand selectivity associated with activation of the transmembrane region of the human follitropin receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Preventive attitude of physicians to avoid OHSS in IVF patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Prevention of severe ovarian hyperstimulation by coasting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Coasting acts through downregulation of VEGF gene expression and protein secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Timed unilateral ovarian follicular aspiration prior to administration of human chorionic gonadotrophin for the prevention of severe ovarian hyperstimulation syndrome in in-vitro fertilization: a prospective randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

The use of albumin in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Inactivation of viral and prion pathogens by gamma-irradiation under conditions that maintain the integrity of human albumin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Severe ovarian hyperstimulation syndrome: is it really preventable by prophylactic intravenous albumin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: a Cochrane review

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Low-molecular-weight dextran infusion is more effective for the treatment of hemoconcentration due to severe ovarian hyperstimulation syndrome than human albumin infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Induction of the endogenous gonadotrophin surge for oocyte maturation with intra-nasal gonadotrophin-releasing hormone analogue (buserelin): effective minimal dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.021

21 January 2018

Identifiers

DOI

10.1196/ANNALS.1365.021

1 reference

16 August 2017

1 reference